NSG 6005 WEEK 1 QUIZ 2026
CLINICAL SCRIPT SOLVED
QUESTIONS VERIFIED ANSWERS A+
◉ Up to 21% of Asians are ultra-rapid 2D6 metabolizers, leading to:
1. A need to monitor drugs metabolized by 2D6 for toxicity
2. Increased dosages needed of drugs metabolized by 2D6, such as the
selective serotonin reuptake inhibitors
3. Decreased conversion of codeine to morphine by CYP 2D6
4. The need for lowered dosages of drugs, such as beta blockers.
Answer: 2. Increased dosages needed of drugs metabolized by 2D6, such
as the selective serotonin reuptake inhibitors
◉ Rifampin is a nonspecific CYP450 inducer that may:
1. Lead to toxic levels of rifampin and must be monitored closely
2. Cause toxic levels of drugs, such as oral contraceptives, when
coadministered
,3. Induce the metabolism of drugs, such as oral contraceptives, leading
to therapeutic failure
4. Cause nonspecific changes in drug metabolism.
Answer: 3. Induce the metabolism of drugs, such as oral contraceptives,
leading to therapeutic failure
◉ Inhibition of P-glycoprotein by a drug such as quinidine may lead to:
1. Decreased therapeutic levels of quinidine
2. Increased therapeutic levels of quinidine
3. Decreased levels of a coadministered drug, such as digoxin, that
requires P-
glycoprotein for absorption and elimination
4. Increased levels of a coadministered drug, such as digoxin, that
requires P-
glycoprotein for absorption and elimination.
Answer: 4. Increased levels of a coadministered drug, such as digoxin,
that requires P-
glycoprotein for absorption and elimination
,◉ Warfarin resistance may be seen in patients with VCORC1 mutation,
leading to:
1. Toxic levels of warfarin building up
2. Decreased response to warfarin
3. Increased risk for significant drug interactions with warfarin
4. Less risk of drug interactions with warfarin.
Answer: 2. Decreased response to warfarin
◉ Genetic testing for VCORC1 mutation to assess potential warfarin
resistance is required prior to prescribing warfarin.
1. True
2. False.
Answer: 2. False
◉ Pharmacogenetic testing is required by the U.S. Food and Drug
Administration prior to prescribing:
1. Erythromycin
, 2. Digoxin
3. Cetuximab
4. Rifampin.
Answer: 3. Cetuximab
◉ Carbamazepine has a Black Box Warning recommending testing for
the HLA-
B*1502 allele in patients with Asian ancestry prior to starting therapy
due to:
1. Decreased effectiveness of carbamazepine in treating seizures in
Asian patients with the HLA-B*1502 allele
2. Increased risk for drug interactions in Asian patients with the HLA-
B*1502 allele
3. Increased risk for Stevens-Johnson syndrome in Asian patients with
HLA-B*1502 allele
4. Patients who have the HLA-B*1502 allele being more likely to have a
resistance to carbamazepine.
CLINICAL SCRIPT SOLVED
QUESTIONS VERIFIED ANSWERS A+
◉ Up to 21% of Asians are ultra-rapid 2D6 metabolizers, leading to:
1. A need to monitor drugs metabolized by 2D6 for toxicity
2. Increased dosages needed of drugs metabolized by 2D6, such as the
selective serotonin reuptake inhibitors
3. Decreased conversion of codeine to morphine by CYP 2D6
4. The need for lowered dosages of drugs, such as beta blockers.
Answer: 2. Increased dosages needed of drugs metabolized by 2D6, such
as the selective serotonin reuptake inhibitors
◉ Rifampin is a nonspecific CYP450 inducer that may:
1. Lead to toxic levels of rifampin and must be monitored closely
2. Cause toxic levels of drugs, such as oral contraceptives, when
coadministered
,3. Induce the metabolism of drugs, such as oral contraceptives, leading
to therapeutic failure
4. Cause nonspecific changes in drug metabolism.
Answer: 3. Induce the metabolism of drugs, such as oral contraceptives,
leading to therapeutic failure
◉ Inhibition of P-glycoprotein by a drug such as quinidine may lead to:
1. Decreased therapeutic levels of quinidine
2. Increased therapeutic levels of quinidine
3. Decreased levels of a coadministered drug, such as digoxin, that
requires P-
glycoprotein for absorption and elimination
4. Increased levels of a coadministered drug, such as digoxin, that
requires P-
glycoprotein for absorption and elimination.
Answer: 4. Increased levels of a coadministered drug, such as digoxin,
that requires P-
glycoprotein for absorption and elimination
,◉ Warfarin resistance may be seen in patients with VCORC1 mutation,
leading to:
1. Toxic levels of warfarin building up
2. Decreased response to warfarin
3. Increased risk for significant drug interactions with warfarin
4. Less risk of drug interactions with warfarin.
Answer: 2. Decreased response to warfarin
◉ Genetic testing for VCORC1 mutation to assess potential warfarin
resistance is required prior to prescribing warfarin.
1. True
2. False.
Answer: 2. False
◉ Pharmacogenetic testing is required by the U.S. Food and Drug
Administration prior to prescribing:
1. Erythromycin
, 2. Digoxin
3. Cetuximab
4. Rifampin.
Answer: 3. Cetuximab
◉ Carbamazepine has a Black Box Warning recommending testing for
the HLA-
B*1502 allele in patients with Asian ancestry prior to starting therapy
due to:
1. Decreased effectiveness of carbamazepine in treating seizures in
Asian patients with the HLA-B*1502 allele
2. Increased risk for drug interactions in Asian patients with the HLA-
B*1502 allele
3. Increased risk for Stevens-Johnson syndrome in Asian patients with
HLA-B*1502 allele
4. Patients who have the HLA-B*1502 allele being more likely to have a
resistance to carbamazepine.
